Congresos

← vista completa

Publicado el 1 de noviembre de 2002 | http://doi.org/10.5867/medwave.2002.10.619

Fármacos hipolipemiantes: estado actual y controversias

Lipid-lowering drugs: current status and controversies

Ada Cuevas

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Ada Cuevas

Pontificia Universidad Católica de Chile, Santiago, Chile

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Cuevas A. Lipid-lowering drugs: current status and controversies. Medwave 2002;2(10):e619 doi: 10.5867/medwave.2002.10.619

Publicación 01/11/2002

Métricas del artículo

Artículo no tiene métricas.

Notas

Referencias

  1. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 Jul 4;286(1):64-70. | CrossRef
  2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999 Dec 3;286(5446):1946-9. | CrossRef | PubMed
  3. R Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet. 2001 Feb 17;357(9255):509-12. | CrossRef
  4. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-Co A reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000 Jun 28;283(24):3211-6. | CrossRef
  5. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000 Nov 11;356(9242):1627-31. | CrossRef
  6. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor. Arch Neurol. 2000 Oct;57(10):1439-43. | CrossRef | PubMed
  7. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci. USA 2001 May 8;98(10):5856-61. | CrossRef | PubMed | Link
  8. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R,et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 1;89(3):268-75. | CrossRef
  9. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ,et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001 Mar 28;285(12):1585-91. | CrossRef
  10. Van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol. 2001 Mar 9;415(1):79-84. | CrossRef
  11. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA,et al.Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001 Aug;23(8):1209-30. | CrossRef
  12. Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism. 2001 Oct;50(10):1234-41. | CrossRef | PubMed
  13. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA,et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001 Aug;23(8):1209-30. | CrossRef